FDA Issues Draft Guidance on Promotion on Internet and Social Media Platforms

more+
less-

On June 17, 2014, the FDA issued long-awaited draft guidance documents addressing two challenges related to use of social media to communicate about FDA regulated products: dissemination of information in character-limited forums and the correction of third-party misinformation. While helpful in certain respects, these draft guidance documents reveal a reluctance by the agency to modify existing policies to accommodate unique characteristics of social media.

Draft Guidance for Industry on Internet/Social Media Platforms with Character Space Limitations – Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices

This draft guidance addresses presentation of information on product risks and benefits in the context of electronic/digital platforms with character and space limitations. These include "microblog" platforms like Tweets and online sponsored links rather than to product websites or webpages on social networking platforms like Facebook, Twitter, or YouTube.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Draft Guidance, Facebook, FDA, Google, Medical Devices, Prescription Drugs, Social Networks, Twitter, YouTube

Published In: Administrative Agency Updates, Communications & Media Updates, Consumer Protection Updates, Health Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Venable LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »